If you haven’t fielded a question about GLP-1 coverage yet this year, you will soon. CMS quietly launched a new demonstration program on July 1 called the Medicare GLP-1 Bridge, and it’s exactly the kind of thing that shows up in your inbox as “my doctor mentioned something about Medicare covering Wegovy now — is that true?” The short answer is yes, sort of, for some people, under a program that runs outside the plans you normally sell. Here’s what you actually need to know to answer that question.
What the Bridge Actually Is
The Medicare GLP-1 Bridge is a short-term federal demonstration, not a permanent benefit and not a change to Part D itself. It runs from July 1, 2026, through December 31, 2027, and it exists to solve a specific problem: Part D plans have never been allowed to cover GLP-1 drugs when they’re prescribed purely for weight loss. If a client’s GLP-1 prescription is for Type 2 diabetes or an approved cardiovascular indication, it’s already covered the normal way through their Part D plan, same as always. The Bridge only steps in when the drug is prescribed strictly for chronic weight management.
Because it’s a demonstration and not a permanent Part D benefit, it sits entirely outside the normal coverage and payment flow. Part D sponsors don’t carry any risk for it, and — this is the part worth remembering — plans don’t have to opt in for their members to use it. It’s available to eligible beneficiaries regardless of which Part D or Medicare Advantage plan they’re enrolled in.
What this means for you: This isn’t a formulary feature you’ll see when comparing plans during AEP, and it’s not something a carrier is offering as a supplemental benefit. It runs on its own track, so don’t expect it to show up as a differentiator between competing plans.
Who Actually Qualifies
Eligibility isn’t automatic just because a client wants to lose weight. CMS set clinical criteria built around BMI thresholds combined with specific health conditions — generally a BMI of 30 or higher paired with a qualifying condition like heart failure, uncontrolled hypertension, or chronic kidney disease, or a BMI of 27 or higher paired with a somewhat broader list of qualifying conditions. The exact criteria and how they’re documented is a clinical determination, not something you or I get to interpret for a client.
That’s the key point to get across when this comes up: eligibility is decided by the client’s prescribing doctor, not by CMS directly and definitely not by an agent. The provider has to submit a prior authorization request confirming the client meets the criteria, and that request goes to a central processor CMS designated for the program — not to the client’s Part D plan. If your client wants to explore this, the right next step is a conversation with their doctor, not a call to their plan’s member services line.
What this means for you: When a client brings this up, your job is to explain how the program works and point them toward their provider — not to guess whether they’d qualify. That’s medical criteria, and it’s outside your lane.
What It Costs and Which Drugs Are Covered
For eligible beneficiaries, the copay is a flat $50. Because the Bridge operates outside the standard Part D payment structure, that $50 doesn’t apply the Part D deductible, doesn’t count toward TrOOP, and there’s no Low-Income Subsidy reduction available on it — LIS just doesn’t apply here the way it would to a normal Part D drug.
The program doesn’t cover every GLP-1 on the market. It’s limited to GLP-1 drugs specifically approved for weight management — think Wegovy and Zepbound, along with newer entrants as they come online — not the versions of these same drug classes approved for diabetes, like Ozempic or Mounjaro. If a client is already getting one of those through Part D for diabetes, nothing changes for them; they stay right where they are.
What this means for you: If a client asks whether this will lower their out-of-pocket costs on a drug they’re already taking for diabetes, the answer is almost certainly no — this program is specifically for the weight-loss indication, not the diabetes one.
Why This Matters for Your Conversations This Year
You don’t sell this program, and you can’t enroll anyone in it — there’s no separate enrollment step at all. But you’re still going to hear about it, particularly from clients who watch the news or who’ve seen a doctor recently and had it mentioned to them. Being able to explain clearly what it is, who it’s for, and where the decision actually gets made will do more for your credibility than trying to sound like an expert on clinical eligibility criteria you’re not licensed to interpret.
It’s also worth knowing this program exists independent of any plan you might be discussing with a client during a review. If someone asks whether switching Part D plans would help them get GLP-1 coverage for weight loss, the honest answer is that switching plans doesn’t touch this — the Bridge runs the same way regardless of which Part D plan they’re in.
What this means for you: Keep the explanation simple: it’s a temporary federal program, it runs through the end of 2027, their doctor decides eligibility, and it has nothing to do with which Part D plan they choose. That’s usually all a client needs to hear to feel like their question was actually answered.
The Bottom Line
The GLP-1 Bridge isn’t something you’ll manage as part of a plan comparison, but it is something your clients will ask about, especially as awareness spreads through their doctors’ offices and the news. Knowing the shape of the program — what it costs, who decides eligibility, and where it sits outside normal Part D — means you can give a straight answer instead of a shrug, and that’s worth something even on a topic you don’t sell.
If you’re working with National Insurance Markets and want a one-page reference to keep handy for client calls on this, reach out to your NIM contact.
References [1] Centers for Medicare & Medicaid Services. “Medicare GLP-1 Bridge.” CmsMedicare GLP-1 Bridge | CMS [2] Centers for Medicare & Medicaid Services. “Information for Providers: Medicare GLP-1 Bridge.” CmsInformation for Providers | CMS [3] Centers for Medicare & Medicaid Services. “Information for Pharmacies: Medicare GLP-1 Bridge.” CmsInformation for Pharmacies | CMS
